GILEAD SCIENCES INC | 54.87 / -0.80% |
Date/Time | 01/22 / 17:32 |
Chg. / Chg.(%) | -0.44 / -0.80% |
Bid | - |
Ask | - |
Open | 54.80 |
Previous Close | 55.31 |
High | 54.98 |
Low | 54.55 |
Volume [EUR] | 55,856.51 |
Volume [Units] | 1,020 |
Price fixings | 19 |
ISIN | US3755581036 |
Security | GILD |
Exchange | Vienna Global Market |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Lang & Schwa.. | 55.060 | ![]() |
|
NASDAQ | 66.9400 | ![]() |
4,914,433 |
Cboe US | 66.98 | ![]() |
297,462 |
IEX | 66.99 | ![]() |
233,318 |
London Inter.. | 66.68 | ![]() |
15,319 |
TradeGate | 55.180 | ![]() |
10,696 |
Xetra | 54.91 | ![]() |
6,568 |
Vienna Globa.. | 54.87 | ![]() |
1,020 |
Stuttgart | 55.240 | ![]() |
942 |
Borsa Italia.. | 54.94 | ![]() |
835 |
Frankfurt | 55.3000 | ![]() |
600 |
Mexico | 1,314.01 | ![]() |
530 |
gettex | 55.190 | ![]() |
309 |
Hamburg | 54.65 | ![]() |
150 |
Borsa Italia.. | 55.44 | ![]() |
100 |
Berlin | 54.92 | ![]() |
57 |
Hannover | 54.82 | ![]() |
0 |
München | 55.12 | ![]() |
0 |
Düsseldorf | 55.18 | ![]() |
0 |
News
- NICE recommends Jyseleca® ▼(filgotinib) on NHS in landmark decision for rheumatoid arthritis
01/21/2021 / 08:08 - GlobeNewswire - Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
01/13/2021 / 14:00 - GlobeNewswire - Gilead holds 25.54% of Galapagos shares
01/11/2021 / 22:01 - GlobeNewswire - Remdesivir could work against new COVID strains - Gilead
01/11/2021 / 15:21 - TeleTrader - Intercept Appoints Jared M. Freedberg as General Counsel and Secretary
01/11/2021 / 14:00 - GlobeNewswire